Antibiotics | CA-KpBSI (n = 240) | HCA-KpBSI (n = 313) | p |
---|---|---|---|
(Non-susceptible/T (%)) | (Non-susceptible/T (%)) | ||
Ciprofloxacin | 12/240 (5.0) | 36/313 (11.5) | 0.007 |
Extended-spectrum cephalosporin | 8/240 (3.3) | 29/313 (9.3) | 0.006 |
  Cefotaxime | 8/240 (3.3) | 25/313 (8.0) | 0.022 |
  Ceftazidime | 6/240 (2.5) | 25/313 (8.0) | 0.005 |
ESBL-productiona | 2/237 (0.8) | 16/310 (5.2) | 0.006 |
Piperacillin plus tazobactam | 6/239 (2.5) | 19/311 (6.1) | 0.045 |
Aztreonam | 5/175 (2.9) | 26/253 (11.1) | 0.004 |
Imipenem | 1/240 (0.4) | 1/313 (0.3) | 1.000 |
Amikacin | 7/240 (2.9) | 17/313 (5.4) | 0.150 |
Gentamicin | 6/240 (2.5) | 22/313 (7.0) | 0.016 |
Tobramycin | 7/177 (4.0) | 26/253 (10.3) | 0.015 |